• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Strong Q4 M&A momentum expected to continue into 2014

Report: Strong Q4 M&A momentum expected to continue into 2014

February 12, 2014
CenterWatch Staff

Pharmaceutical and life sciences (PLS) merger and acquisition volume and value increased in the fourth quarter of 2013, finishing the year for deal activity on a high note,according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued by PwC. PwC’s Health Industries Group is an advisor to public and private organizations across the health industries.

“We expect the momentum of M&A activity in the fourth quarter, driven by macroeconomic stability and growth in key markets, to continue into 2014 as acquirers remain active in the market. Working with clients on their M&A strategies, we’re seeing a continued focus on successful execution and PLS companies are continuing to use earn-outs and other deal tools to bridge value gaps, share risk and complete deals,” said Dimitri Drone, U.S. Pharmaceutical and Life Sciences Deals leader, PwC. 

There were 31 PLS transactions in the fourth quarter of 2013, a 24% increase from the 25 deals in the third quarter of 2013. Total deal value also jumped more than 100% to $37.1 billion in the fourth quarter compared to $18 billion in both the third quarter of 2013 and the fourth quarter of 2012. 

On an annual basis, deal volume decreased by 15 deals—or 11%—for the full year, but deal value rose nearly 46% compared to 2012. While deal values totaled more than $140 billion in 2013, the PLS industry didn’t experience any of the mega deals that were prevalent in years past. Rather, large pharmaceutical companies focused on rebuilding their product pipelines through acquisitions of relatively smaller biopharmaceutical players, as well as balancing their own product portfolios and seeking to unlock value through divestitures, according to PwC. 

Eleven divestitures were completed in the fourth quarter of 2013, representing a total value of $3.8 billion, as they continue to be a key component of PLS companies’ strategies to maximize shareholder value. Additionally, strategic buyers continue to account for the majority of M&A activity in the PLS industry. While financial buyers remain active in deal processes, the report notes that potential synergies and other benefits of transactions have driven a higher rate of success for strategic acquirers. 

Looking at the PLS industry sectors, medical device manufacturers remained active in M&A with 15 deals in the fourth quarter, primarily in middle-market transactions, as they sought to complement existing product portfolios with innovative technologies. While pharmaceutical companies represented 12 deals in the fourth quarter, they continued to face increased competition in deal-making from biotechnology companies seeking to gain scale and mitigate risk through a more diverse product portfolio. The diagnostics and services sectors remained relatively quiet in the M&A market throughout 2013.

“Looking forward, healthy balance sheets, access to financing and strong equity markets will allow PLS deal makers to continue to seek opportunities to grow through acquisition across industry sectors in 2014,” said Drone. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing